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SUMMARY
Internationally 3% of the donor hearts are distributed to re-transplant
patients. In Eurotransplant, only patients with a primary graft dysfunction
(PGD) within 1 week after heart transplantation (HTX) are indicated for
high urgency listing. The aim of this study is to provide evidence for the
discussion on whether these patients should still be allocated with priority.
All consecutive HTX performed in the period 1981–2015 were included.
Multivariate Cox’ model was built including: donor and recipient age and
gender, ischaemia time, recipient diagnose, urgency status and era. The
study population included 18 490 HTX, of these 463 (2.6%) were repeat
transplants. The major indications for re-HTX were cardiac allograft vascu-
lopathy (CAV) (50%), PGD (26%) and acute rejection (21%). In a multi-
variate model, compared with first HTX hazards ratio and 95% confidence
interval for repeat HTX were 2.27 (1.83–2.82) for PGD, 2.24 (1.76–2.85)
for acute rejection and 1.22 (1.00–1.48) for CAV (P < 0.0001). Outcome
after cardiac re-HTX strongly depends on the indication for re-HTX with
acceptable outcomes for CAV. In contrast, just 47.5% of all hearts trans-
planted in patients who were re-transplanted for PGD still functioned at
1-month post-transplant. Alternative options like VA-ECMO should be
first offered before opting for acute re-transplantation.
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Introduction
Attributable to surgical and medical advances, heart
transplantation has become the preferred treatment
option in selected patients with end-stage heart failure.
Over the last three decades graft survival rates have sig-
nificantly improved, but many patients who underwent
heart transplantation will eventually have complications
resulting in allograft failure [1,2].
Three percent of the available donor hearts are
currently distributed to re-transplant patients [1]. In
Eurotransplant (ET) the indications for high urgent list-
ing of patients needing a cardiac re-transplantation have
sharpened over the years (Table 1), but those in need of a
re-transplantation have, in contrast with the situation in
the US, always received priority in organ allocation [3].
As an integral part of the development of a new allo-
cation scheme based on benefit instead of urgency, spe-
cial recipient groups who cannot be judged by a score
were defined; one of these groups consists of re-trans-
plant candidates. The working group on the Cardiac
Allocation Score convened in Leiden, the Netherlands
on October 6, 2015 to discuss outcomes following
re-transplantation [4]. Until the cardiac allocation score
(CAS) system will be implemented, the urgency tier sys-
tem will still determine the allocation policy. In its cur-
rent form, patients suffering a primary graft dysfunction
within 1 week after heart transplantation are indicated
for high urgency (HU) listing.
There are three major ethical issues affecting alloca-
tion policy for repeat transplantation [5]. These three
ethical considerations are the following: (i) the obliga-
tion a transplant team has to continue to offer the best
possible care to a patient they previously transplanted,
(ii) the fairness of assigning a second allograft while
others die awaiting their first, and (iii) the difference in
utility between primary and re-transplantation. Argu-
ments to deny a heart re-transplant are usually based
on this latter point, namely futility of the intervention,
where medically futility is interpreted as an unaccept-
able likelihood of achieving life prolongation or a thera-
peutic benefit [6].
In Eurotransplant one of five patients listed for a first
heart transplantation dies on the waiting list within
3 years [7]. International data show that
re-transplantation yields worse results compared with
primary transplants, where the indication for the repeat
transplant strongly determines the prognosis [8–10].
The aim of this study is to examine the outcome
after cardiac re-transplantation in the Eurotransplant
cohort of 35 years in order to provide evidence for the
discussion, whether patients suffering from primary
graft dysfunction (PGD) within 1 week after heart
transplantation should still be allocated heart allografts
with high priority.
Materials and methods
Study design
Retrospective study including all consecutive heart
transplantations performed in the Eurotransplant area.
Study population
All consecutive heart transplantations performed between
January 1981 and December 2015 were included.
Statistical analysis
Survival rates were examined with time-to-event analy-
sis in which the event was defined as graft failure, with
censoring for death with functioning graft. For re-trans-
plants, survival was computed from the date of the
re-transplant.
Multivariate analysis included the following factors:
donor and recipient age, donor and recipient gender,
ischaemia time, recipient diagnose, urgency status and
era of the transplant.
Continuous variables were analysed using Wilcoxon-
Mann-Whitney test, while Chi-square statistics were
used to compare categorical variables. Survival analyses
were performed by Kaplan–Meier method. Survival rates
were compared using the log-rank test. All analyses were
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performed using SAS STATISTICAL program version 9.1
(SAS Institute, Cary, NC, USA). A P-value below 0.05
was considered statistically significant.
Results
Demographics
The study population included 18 490 heart transplants,
of these 463 (2.6%) were repeat transplants with
447 second transplants, 15 third transplants and one
patient received four heart transplants. The major indi-
cations for cardiac re-transplantation were cardiac allo-
graft vasculopathy (50%), primary graft dysfunction
(26%) and acute rejection (21%). Median time between
the first and the re-transplants was 2 years and
10 months and ranged between 0 days and 27 years and
11 months. Donor, recipient and transplant characteris-
tics are shown in Table 2. Re-transplant rates over time
have been stable around 2.5% (Fig. 1), but indications
for re-transplantation have shifted in this 35 year period
(Fig. 2). In the early years a majority of patients were
re-transplanted following acute rejection and PGD,
while in the latter decade the major indication for heart
re-transplantation was cardiac allograft vasculopathy.
Survival rates – Univariate analysis
Graft survival rates for cardiac re-transplants in the
Eurotransplant cohort have improved over time with 1-
month, 1- and 5-year rates of 63.2%, 43.5%, 37.9% and
67.9%, 59.3%, 48.6% and 87.5%, 73.5%, 62.1% and
86.7%,75.8%, 66.7% for patients re-transplanted in the
period: 1981–1991 and 1992–2001 and 2002–2005 and
2006–2015, respectively (P < 0.0001) (Fig. 3).
Outcome after cardiac re-transplantation is compared
with other diagnoses significantly worse (P < 0.0001)
(Fig. 4). The 1-month, 1- and 5-year graft survival rates
by indication were for coronary artery disease: 86.8%,
76.0% and 64.8%; for cardiomyopathy: 89.1%, 79.8%,
and 70.5%; for congenital: 83.0%, 76.2% and 69.3%; for
valvular diseases: 83.6%, 72.2% and 65.7%, for other:
85.9%, 75.2% and 66.1% and for re-transplantation:
74.4%, 62.3% and 53.1%.
Figure 5 shows the graft survival by indication for re-
transplants and the outcome of first transplants. Com-
pared with first transplant, patient re-transplanted after
cardiac allograft vasculopathy (CAV) fared equally well
with 1-month, 1- and 5-year rates of 89.5%, 79.3% and
67.8% for patient re-grafted after CAV and 87.9%,
78.0%, 68.3% for first HTX (P = 0.54). The graft sur-
vival for patients re-transplanted after PGD or rejection
fared worse compared with first transplants with
1-month, 1- and 5-year rates of 47.5%, 39.7% and
35.1% for PGD and 70.9%, 51.9% and 40.6% for rejec-
tion (P < 0.0001).
The interval between transplants is significantly asso-
ciated with graft survival (P < 0.0001) (Fig. 6). Early or
acute re-transplants (<31 days) yielded 1-month, 1- and
5-year graft survival rates of 49.6%, 40.9% and 34.8%.
If the interval was between 31 and 364 days the
1-month, 1- and 5-year graft survival rates were at
69.8%, 46.7% and 38.7%, and if the interval was
365 days or longer the 1-month, 1- and 5-year graft
survival rates were: 88.3%, 76.8% and 64.7%.
Factors associated with overall graft survival –
multivariate analysis
Donor and recipient age, recipient gender, cold
ischaemia time, era of transplant and the indication
for re-transplantation were found to be significantly
associated with graft outcome (Table 3). The multi-
variate model showed that all three major indications
Table 1. Overview of heart allocation policies for re-
transplantation.
HU status for all acute re-transplantation <3 days (before
August 23, 2000)
No audit
Same rule for children (<16 years)
No international priority
HU status for all acute re-transplantation <3 days (August
23, 2000–August 31, 2005)
International audit
Same rule for children (<16 years), but no audit if <45 kg
International priority
HU status for PGD <1 week (September 1, 2005–present)
International audit
Same rule for children (<16 years), but no audit if <45 kg
International priority
Only if VAD implant is not possible or has limited chances
for success
HU status for all children (April 21, 2011–present)
No audit
International priority
Pediatric status*
*A transplant candidate with a paediatric status is a patient,
who at time of organ offer for heart transplantation is under
the age of 16 years or older but proven to be in maturation.
This proof has to be delivered by the transplant centre by a
report from a competent radiologist or paediatric endocrinol-
ogist on an X-ray of the left hand, not older than 3 months.
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of repeat HTX have a significantly worse outcome
compared with first HTX with hazards ratio (HR)
and 95% confidence interval (CI) of 2.27 (1.83–2.82),
2.24 (1.76–2.85), 1.22 (1.00–1.48) and 1.96 (0.98–
3.93) for repeat Htx for PGD, rejection, CAV and
other, respectively (P < 0.0001).
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Figure 1 Number of transplants by indication in the Eurotransplant cohort. Coronary artery disease (blue bar), cardiomyopathy (green bar),
congenital (orange bar), re-transplantation (black bar), valvular (red bar), other (yellow bar).
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Figure 2 Number of heart re-transplantations by indication. Cardiac allograft vasculopathy (geen bar), primary graft dysfunction (orange bar),
rejection (red bar), other causes (blue bar).
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Figure 3 Graft survival of all
consecutive heart re-transplants
performed in Eurotransplant in the
period 1981–2015 by period. Period:
1981–1991 [N = 102] (blue line),
1992–2001 [N = 170] (green line),
2002–2005 [N = 65] (red line), 2006–
2015 [N = 126] (purple line).
Figure 4 Graft survival of all
consecutive heart transplants
performed in Eurotransplant in the
period 1981–2015 by indication.
Coronary artery disease [N = 4951]
(blue line), cardiomyopathy
[N = 10 385] (green line), congenital
[N = 449] (orange line), re-
transplantation [N = 463] (black line),
valvular [N = 395] (red line), other
[N = 1847] (yellow line).
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Discussion
In Eurotransplant 2–3% of the available hearts are cur-
rently distributed to re-transplant patients where every
year between 10 and 15 patients receive a second heart
transplant.
Our data show that cardiac re-transplantation out-
come has improved over the decades, but is still inferior
to primary transplantation. Outcome after cardiac
re-transplantation depends on the indication for re-
transplantation, and a shift in indication favouring the
patients re-transplanted for cardiac allograft vasculopathy
in the most recent years, is partly accountable for this
improvement. In this 35 years Eurotransplant cohort,
when compared with outcome after primary transplanta-
tion, graft survival for patients re-transplanted following
primary graft dysfunction and rejection was significant
worse with hazards ratios of 2.27 and 2.24 respectively,
while the risk of graft loss for patients re-transplanted for
cardiac allograft vasculopathy was 1.22.
Allocation rules are conceived and decided upon by
clinicians – collaborating in the international organ
advisory committee – but whose first job is to care for
transplant candidates and recipients. As a consequence,
since the early days acute re-transplantation has always
been a standard indication for listing on the high
urgency waiting list as this rule facilitates and supports
the transplant teams that consider their patient eligible
for acute re-transplantation [7]. However, with growing
organ shortage, the role of the policy makers has chan-
ged towards being also the guardian of a shared scarce
commodity where the fairness of assigning a second
graft while other die awaiting their first, is a substantial
ethical issue.
The graft survival rates for patients re-transplanted in
Eurotransplanted after PGD at 1-month, 1- and 5-years
were 47.5%, 39.7% and 35.1%, respectively. Given these
jeopardized results, the Eurotransplant Thoracic Advi-
sory Committee is currently discussing whether the allo-
cation priority currently assigned to patients with PGD
Figure 5 Graft survival of all consecutive heart transplants performed in Eurotransplant in the period 1981–2015 by indication for Re-trans-
plants versus first transplants. First transplant [N = 18 027] (blue line), cardiac allograft vasculopathy [N = 233] (green line), primary graft dys-
function [N = 119] (orange line), rejection [N = 98] (red line). Note the group other [N = 13] is not shown.
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can be sustained. Until recently the only therapeutic
option for PGD was a re-HTX. During the latest con-
sensus conference on PGD after cardiac transplantation
and confirmed by single centre experiences temporary
ventricular assist devices and veno-arterial extracorpo-
real membrane oxygenation (VA-ECMO) can now be
seen as established effective treatment options for severe
PGD whose intervention can preclude emergency sal-
vage re-transplantation [11,12]. In the majority of cases
(75–87%), donor hearts recovered and patients could be
weaned from ECMO support with acceptable survival
(55–70%) [13]. In the absence of randomized clinical
trials, extracorporeal life support (ECLS) as bridge to
recovery for severe PGD after heart transplant continues
to be the first line of support with some recent evidence
of improved outcomes as compared with short-term
VAD use [14]. Based on the acceptable success rate of
ECMO bridge to recovery and the better survival rates
compared with those after acute re-transplantation we
would consider a patient eligible for re-transplantation
because of PGD only if he cannot be weaned from
mechanical support, if he has good end-organ function
(besides donor heart, kidney, liver, lung) and if he has a
normal neurological condition.
Center volume and patient survival are consistently
shown to be positively related in the ISHLT database
[1]. As a result of its international composition in Euro-
transplant this association is not so obvious as a large
program in one country might be considered small in
another country [15]. However the centre’s expertise is
instrumental in dealing with complicated cases and pro-
tocols for PGD treatment should be available and regu-
larly be audited.
Acute rejection accounted for 21% of all cardiac re-
transplants in our total study cohort. Compared with first
transplants, patient re-transplanted after rejection fared
worse with 1-month, 1- and 5-year rates of 70.9%, 51.9%
and 40.6%, respectively. However, during the last decade
acute rejection as indication for re-transplantation has
become an infrequent event. This is related to the fact
that refractory acute rejection is rarely seen because of
improvements with diagnosis allowing identification of
high risk patients, early detection of events and because
of improved treatment options like extracorporeal
Figure 6 Graft survival of all consecutive heart re-transplants performed in Eurotransplant in the period 1981–2015 by interval between the
transplants. Interval between first and re-transplant ≤31 days [N = 141] (black line), between 32 and 364 days [N = 50] (blue line), ≥365 days
[N = 270] (green line).
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pheresis, the availability of new antibodies and better
maintenance immunosuppression [16]. Monitoring
immunosuppressive drug intake compliance should be
rigidly undertaken; many of the patients with refractory
severe rejection had adherence problems with medication
and are therefore ineligible for re-transplantation [17].
Current graft surveillance protocols for acute rejec-
tion entail invasive endo-myocardial biopsy, further
research should focus on refining molecular analysis as
a diagnostic tool [18]. This will be achieved by refining
reference sets through accurate phenotyping of biopsy
samples. Non-invasive biomarkers can then be refined
according to the true pathological picture by using
molecular analysis as a benchmark rather than subjec-
tive histology readings [19,20].
Our data show that outcome for patients re-trans-
planted after suffering CAV is excellent with 1-month,
1- and 5-year rates of 89.5%, 79.3% and 67.8%, respec-
tively. However, with the availability of good long-term
viable alternatives based on pharmacological manage-
ment and percutaneous coronary intervention strategies,
re-transplantation should be restricted to selected
patients with CAV [21,22]. Again, prevention is key
and surveillance strategies by invasive angiography
and intravascular ultrasound should be set up and
executed [23].
The limitations of this study are inherent to using
registry data obtained from different transplant centres
on a voluntary basis and where standardization of the
definition of clinical events is difficult. Sabatino et al.
[24] have recently shown that it is crucial not only to
determine the aetiology of the graft dysfunction but
most importantly it is to know the severity of the PGD
as this will determine the clinical management strategy
and the patient outcome. However, as the standard defi-
nitions and the grading system for PGD in heart trans-
plantation only appeared in 2014, our data contain
events using different definitions for PGD [11].
In conclusion, our data show that cardiac re-trans-
plantation outcome has improved over the decades, but
is still inferior to primary transplantation. Outcome
after cardiac re-transplantation depends on the indica-
tion and hence on the time span between the first and
the re-transplantation. Only 47.5% of all hearts trans-
planted in patients who were re-transplanted for pri-
mary graft dysfunction still functioned at 1-month
post-transplant. Alternative therapeutic options like VA-
ECMO should be first offered before opting for an acute
Table 3. Multivariate model for risk factors for graft failure.
Variable
Hazard
ratio
95%
Confidence
interval P-value
Type HTX
First HTX 1
Repeat for PGD 2.27 1.83–2.82 <0.0001
Repeat for rejection 2.24 1.76–2.85 <0.0001
Repeat for CAV 1.22 1.00–1.48 0.049
Repeat for other 1.96 0.98–3.93 0.057
Era
2006–2015 1
2002–2005 1.05 0.97–1.15 0.23
1992–2001 1.32 1.23–1.42 <0.0001
1981–1991 1.74 1.59–1.89 <0.0001
Recipient age 1.01 1.01–1.02 <0.0001
Donor age 1.01 1.0–1.01 <0.0001
Recipient gender
Female 1
Male 1.06 1.00–1.13 0.045
Donor gender
Female 1
Male 0.97 0.93–1.02 0.25
Cold ischaemic time 1.06 1.03–1.09 <0.0001
HU status
Elective 1
HU 1.02 0.95–1.10 0.57
Transplant International 2018; 9
ª 2018 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.
Heart re-transplantation in Eurotransplant
re-transplantation, since a sequential mode of treatment
lowers the individual risk of the transplant patient.
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